MannKind (MNKD) Projected to Post Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect MannKind to post earnings of ($0.02) per share and revenue of $105.3810 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The firm had revenue of $111.96 million during the quarter, compared to the consensus estimate of $99.85 million. MannKind had a negative return on equity of 11.21% and a net margin of 1.68%.The firm’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.03 EPS. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Performance

Shares of NASDAQ MNKD traded up $0.05 during midday trading on Tuesday, hitting $2.86. 2,994,071 shares of the stock traded hands, compared to its average volume of 5,235,165. MannKind has a one year low of $2.23 and a one year high of $6.51. The business has a 50 day moving average price of $2.86 and a two-hundred day moving average price of $4.63. The company has a market cap of $883.16 million, a PE ratio of 143.07 and a beta of 1.04.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MNKD shares. Zacks Research raised shares of MannKind from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Mizuho lowered their price objective on shares of MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Wall Street Zen cut shares of MannKind from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of MannKind in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $3.50 target price (down from $7.50) on shares of MannKind in a report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, MannKind presently has an average rating of “Moderate Buy” and an average target price of $8.69.

Insider Transactions at MannKind

In other news, CEO Michael Castagna acquired 100,000 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was purchased at an average price of $2.59 per share, for a total transaction of $259,000.00. Following the purchase, the chief executive officer owned 2,575,911 shares in the company, valued at approximately $6,671,609.49. This represents a 4.04% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On MannKind

Institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd increased its position in shares of MannKind by 108.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,927 shares during the last quarter. Lido Advisors LLC purchased a new position in MannKind in the fourth quarter worth $63,000. Mercer Global Advisors Inc. ADV purchased a new position in MannKind in the fourth quarter worth $70,000. Freestone Grove Partners LP bought a new position in MannKind in the 4th quarter valued at $80,000. Finally, Ameriprise Financial Inc. increased its position in shares of MannKind by 45.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 17,055 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 5,300 shares during the last quarter. 49.55% of the stock is owned by institutional investors.

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.